Skip to main content

Table 1 Studies included in this systematic review. Values for age and disease duration are presented as the mean value ± standard deviation, mean value (range) or percentage

From: Oral health-related quality of life in adult patients with end-stage kidney diseases undergoing renal replacement therapy – a systematic review

Author, year

Disease

Country

No. of patients

Study type

Subjects mean age in years

Disease duration

Female (%)

Control group for OHRQoL

Guzeldemir et al. 2009 [17]

HD

Turkey

47

monocentric cross-sectional

46.38 ± 15.10 years

HD: 71.04 ± 1.16 months

48.9%

no

Hajian-Tilaki et al. 2014 [18]

HD

Iran

145

monocentric cross-sectional

58.17 ± 17.76 years

HD: 49.33 ± 46.99 months

46.9%

no

Pakpour et al. 2015 [19]

HD

Iran

512

multicentre cross-sectional

57.7 ± 17.01

HD: 52.12 ± 29.86 months

37.1%

yes, healthy control n = 255, 55.8 ± 15.9 years, 38% female

Schmalz et al. 2016 [20]

HD, KTx

Germany

HD: 87, KTx: 39

multicentre cross-sectional

HD: 60.98 ± 14.01 years, KTx: 56.51 ± 11.56 years

n/a

HD: 37.9% KTx: 51.3%

yes, healthy control n = 91, age: 58.31 ± 9.91 years, 65.9% female

Lopez-Pintor et al. 2017 [21]

HD

Spain

50

monocentric cross-sectional

66.62 ± 13.96 years

HD: 46.02 ± 44.90 months

30%

no

Lira E Silva et al. 2017 [28]

HD

Brazil

226

multicentre cross-sectional

55.52 ± 14.70

HD: < 1 year: 17.3%, 1–5 years: 56.6%, > 5 years 26.1%

40.7%

no

Rodakowska et al. 2018 [22]

HD

Poland

72

monocentric cross-sectional

63.2 ± 15.2 years

HD: 43.8 (1–264) months

60.7%

no

Camacho-Alonso et al. 2018 [23]

HD

Spain

120

multicentre cross-sectional

69.90 ± 11.61 years

HD: < 1 year: 11.7%, 1–2.9 years: 10.8%, 3–4.9 years: 22.5%, 5–9.9 years: 35.8%, > 10 years: 19.2%

31.7%

yes, healthy control n = 120, mean age 67.71 ± 8.96, 37.5% female

Schmalz et al. 2018 [24]

HD

Germany

210

multicentre cross-sectional

64.92 ± 15.7 years

HD: 0–2 years: 15.3%, 3–5 years: 18.4%, 6–8 years 17.9%, 9–12 years 15.3%, 13–20 years 17.9%, > 20 years: 15.3%

35%

no

Ruokonen et al. 2019 [25]

KTx

Finland

51

prospective follow-up cohort study

61 (31–86) years

time since KTx 7.1 (1–11) years

33%

no

Kahar et al. 2019 [26]

HD

USA

70

multicentre cross-sectional

≤65 years: 44.1% > 66 years: 55.9%

4.7 ± 7.5 years

39.7%

no

Oliveira et al. 2019 [27]

HD

Brazil

180

multicentre cross-sectional

51.98 ± 14.34 years

< 12 months: 23.3%, 12–36 months 32.7%, > 36 months

45%

no

  1. OHRQoL oral health-related quality of life, n/a not applicable, HD haemodialysis, KTx kidney transplantation